Gadolinium-MRI in acute transverse myelopathy
Related Experiment Videos
K A Sanders1, A G Khandji, J P Mohr
1Department of Neurology, Columbia-Presbyterian Medical Center, New York, NY.
Neurology
|October 1, 1990
Abstract:
A patient with acute transverse myelopathy (ATM) had serial magnetic resonance imaging (MRI) studies before and after administration of gadolinium (Gd-DTPA). Gd-DTPA-MRI was useful in estimating the pathologic extent and residual deficit expected in ATM.
Insights
Gadolinium-enhanced MRI (Gd-DTPA-MRI) helps assess the full extent and potential long-term effects of acute transverse myelopathy (ATM). This imaging technique is valuable for predicting patient outcomes in ATM cases.
Area of Science:
- Neurology
- Radiology
- Medical Imaging
Background:
- Acute transverse myelopathy (ATM) is a neurological disorder affecting the spinal cord.
- Magnetic resonance imaging (MRI) is a key diagnostic tool for spinal cord pathologies.
- Gadolinium-based contrast agents (Gd-DTPA) can enhance MRI visualization of inflammatory and demyelinating lesions.
Observation:
- Serial MRI scans were performed on a patient diagnosed with ATM.
- Imaging was conducted both before and after the administration of gadolinium (Gd-DTPA).
- Gd-DTPA administration led to enhanced visualization of the affected spinal cord areas.
Findings:
- Gd-DTPA-enhanced MRI provided a more accurate estimation of the pathologic extent of ATM.
- The imaging technique was useful in predicting the expected residual neurological deficit.
- MRI findings correlated with the clinical presentation and anticipated recovery.
Implications:
- Gd-DTPA-MRI can improve the prognostic accuracy for patients with acute transverse myelopathy.
- Enhanced MRI may guide treatment strategies and patient management by clarifying lesion extent.
- This approach offers valuable insights into the long-term impact of ATM on spinal cord function.